Heart failure & cardiomyopathiesMeta-analysis
Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant–Level Analysis of 6 Randomized Clinical Trials
- Pooled individual participant-level analysis of 6 randomised clinical trials
- standardized kidney end point definitions
Authors' conclusion
When applying standardized stringent kidney end point definitions, steroidal mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitor, and SGLT2 inhibitors have either neutral or beneficial effects on kidney outcomes in heart failure.
Study context
- Population
- Patients with HF in 6 contemporary trials
- Participants
- 28,690 patients · 6 RCTs
- Comparison
- Steroidal MRA, ARNI and SGLT2 inhibitors vs control
- Outcome
- Standardized composite kidney end point: sustained eGFR decline by 40%, 50% or 57% (confirmed ≥30 days later), end-stage kidney disease or renal death
Pooled result
As reported in the abstract
Composite kidney end point by eGFR threshold
Proportion with end point, estimated glomerular filtration rate (eGFR) threshold 57%
0.3% to 3.3%
Proportion with end point, eGFR threshold 40%
1.0% to 10.0%
Original publication
Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant–Level Analysis of 6 Randomized Clinical Trials. Circulation. Published 1 September 2024. doi:10.1161/circulationaha.124.071110
Summarised from the published abstract; every number is checked against it